napabucasin (BBI608) / Sumitomo Pharma - LARVOL DELTA

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial. (PubMed, EClinicalMedicine) - P3 | "Our data reinforce the value of nab-paclitaxel plus gemcitabine as a platform for novel therapeutics approaches in mPDAC. The Sumitomo Pharma Oncology, Inc."

Head-to-Head • Journal • Metastases • P3 data • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Oncology • Pain • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • NQO1

Discovery of novel dual STAT3/TrxR1 inhibitors via pharmacophore fusion as potent lead compounds for colorectal cancer. (PubMed, Bioorg Med Chem Lett) - "Herein, guided by a pharmacophore fusion strategy, we rationally designed and synthesized a novel series of STAT3/TrxR1 dual inhibitors by integrating the naphthoquinone core of Napabucasin with the bioactive scaffold of curcumin...Preliminary biosafety evaluations demonstrated that LF39 possesses excellent hemocompatibility with negligible hemolytic toxicity at concentrations up to 100 μM. Taken together, these findings structurally support the STAT3/TrxR1 polypharmacology strategy and present LF39 as a highly promising, rationally designed lead compound for CRC intervention."

Journal • Colorectal Cancer • Oncology • Solid Tumor • STAT3

STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma. (PubMed, Oncoimmunology) - "report that STAT3 inhibition eliminates multiple myeloma stem-like cells while eliciting hallmarks of immunogenic cell death. These highly intriguing findings connect stemness, integrated stress response, and antitumor immunity, yet in vivo validation remains necessary before this strategy can be considered immunogenic."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology

STAT3 inhibition eradicates multiple myeloma stem-like cells and induces immunogenic cell death. (PubMed, Blood Sci) - "Moreover, we revealed that BBI608 triggered immunogenic cell death (ICD) via the activation of endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), which subsequently enhanced T-cell-mediated anti-tumor immunity. Our findings highlight STAT3 inhibition as a promising strategy to simultaneously eradicate MM cells, target stem cell reservoirs, and harness anti-tumor immunity, providing a robust rationale for the clinical translation of BBI608 in MM therapy."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology

Targeting EZH2-driven cholesterol metabolic vulnerability through Napabucasin suppresses ovarian cancer metastasis. (PubMed, Cell Death Dis) - "Notably, Napabucasin effectively inhibited ovarian cancer metastasis in vivo. Collectively, our findings elucidate a previously unrecognized mechanism by which EZH2 governs metastatic progression through cholesterol metabolic rewiring and propose Napabucasin as a promising therapeutic strategy for ovarian cancer, particularly in tumors with EZH2 hyperactivation."

Journal • Gynecologic Cancers • Metabolic Disorders • Oncology • Ovarian Cancer • Solid Tumor • EZH2 • RAP1A

Discovery of novel NQO1/STAT3/HDAC triple-target agents for the treatment of triple negative breast cancer. (PubMed, Bioorg Chem) - "Notably, SHN7 exerted strong in vivo anti-tumor effects relative to napabucasin and SAHA, with minimal toxic effects. Therefore, SHN7 may be a promising NQO1/STAT3/HDAC triple-target agent that can decrease the resistance of TNBC to HDAC inhibitors and can be developed as a candidate anti-TNBC drug."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • NQO1 • STAT3

HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma. (PubMed, J Exp Clin Cancer Res) - "Our findings revealed a signalling pathway in which lung adenocarcinoma regulates stemness and tumourigenesis through HES1, and the targeting of this pathway by VR23 or napabucasin supports further preclinical development for CDK4/6 inhibitor combination therapy."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HES1 • SOX9

A locoregional program of photothermal debulking, stemness suppression, and dendritic cell activation for durable glioblastoma immunotherapy. (PubMed, J Control Release) - "The brain-compliant injectable hydrogel (MIN-PPIC@iGel) co-encapsulates indocyanine green/napabucasin-loaded micelles and poly(I:C)-loaded polymersomes, enabling staged local release for up to 20 days...In a large orthotopic GBM model, this single-shot locoregional therapy combined with anti-CTLA-4 renders 50% of mice tumor-free and establishes durable antitumor immunity. This work provides a material-programmed locoregional strategy for integrating local cytoreduction, stemness control, and immune activation against GBM."

Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

PMN-MDSCs-derived exosomal S100A9 drives breast cancer progression by enhancing cancer stemness and CXCL5-mediated metastatic potential. (PubMed, Cell Death Discov) - "These effects were effectively reversed by the stemness inhibitor Napabucasin...In summary, this study reveals that PMN-MDSCs can activate the STAT3-CXCL5-ERK positive feedback regulatory axis via exosomal S100A9, synergistically enhancing breast cancer cell stemness and metastatic capacity. These findings provide a theoretical reference and potential intervention targets for targeting the tumor microenvironment to inhibit TNBC progression."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CDH1 • CXCL5 • S100A9

Discovery and validation of effective combination therapies targeting cell state-specific master regulator vulnerabilities by network-based protein activity inference in diffuse midline glioma (AACR 2024) - "Candidate drugs predicted by OncoTarget (inhibitors of individual MRs) and OncoTreat were distinct across the cell states, and we selected five drugs targeting the OPC/cycling-like cells (Trametinib, Dinaciclib, Avapritinib, Mocetinostat, and Etoposide), and four drugs targeting the AC-like cells (Ruxolitinib, Venetoclax, Napabucasin, Larotrectonib) for further validation as these states comprised most tumor cells across patients.We generated single-cell RNAseq for 95,687 cells after 5 days of treatment with either vehicle control (n = 4) or candidate drug (n = 2-3/drug) in subcutaneous SU-DIPG-17 mouse models. Notably, the combination of drugs targeting OPC/cycling-like and AC-like cells (i.e. Trametinib+Ruxolitinib and Avapritinib+Venetoclax) showed significantly lower tumor volumes after 2 weeks of treatment as compared to vehicles or each drug alone, and significant survival differences for some combinations. This work provides a precision medicine platform to..."

Combination therapy • Brain Cancer • CNS Tumor • Diffuse Midline Glioma • Glioma • Oncology • Solid Tumor

Parallel drug development strategies for fibrolamellar hepatocellular carcinoma and proteasome-dependent multiple myeloma (AACR 2026) - "The primary model compound of this project, Napabucasin, is a naphthoquinone natural product that has shown wide spectrum anti-cancer activities...Among all three, the chymotrypsin-like β5 activity remains the primary driver of cytotoxicity for clinically approved inhibitors such as bortezomib, carfilzomib; however, their therapeutic use is limited by toxicity...This project evaluates newly synthesized cystargolide analogs for cytotoxicity, bioavailability, and proteasome inhibition in RPMI-8226 myeloma cells. Using cell-based assays and IC₅₀ determination, we aim to establish structure activity relationships and advance optimized β-lactone inhibitors with improved therapeutic potential."

Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Multiple Myeloma • Oncology • Solid Tumor • DNAJB1 • PRKACA

Inhibiting interferon-gamma-stimulated melanoma progression by disrupting the crosstalk between nNOS/NO and COX-2 (AACR 2026) - "Cotreatment with celecoxib, a selective COX-2 inhibitor, effectively diminished these changes induced by PGE2...STAT3 inhibitor napabucasin also inhibited COX-2 expression both in the presence and absence of IFN-γ...PBMCs from a significant portion of donors (64%) were reactivated by HH044 pretreatment, displaying a significant increase in IL-2+ T cells after coincubation with melanoma cells.Our study reveals a positive feedback loop linking nNOS-mediated NO signaling to the COX-2/PGE2 signaling axis in melanoma, thereby further enhancing the pro-tumorigenic activity of IFN-γ. Disrupting crosstalk between nNOS/NO and COX-2 with selective inhibitors effectively suppressed melanoma tumor growth, possibly by modulating the tumor immune microenvironment."

IO biomarker • Melanoma • Oncology • Solid Tumor • IFNG • PD-L1 • PTGS2

NAD(P)H: Quinone oxidoreductase 1 (NQO1): Is it a potential molecular target in colorectal cancer? (AACR 2026) - "According to a meta-analysis and computational technique, NQO1 is a valid biomarker and possible molecular target in CRC. In vitro studies revealed that suppressing NQO1 with BBI 608 reduced cell growth in both CRC cell lines. Knockout, overexpression, and site-directed mutagenesis are necessary for a deeper understanding of BBI 608-targeted NQO1 and its amino acid residues."

Colorectal Cancer • Oncology • Solid Tumor • NQO1

Development of hypoxia responsive targeted polymersomes drug therapy validated using patient derived xenograft of triple negative breast cancer (AACR 2024) - "TNBC accounts for 20% of breast cancer and is more aggressive due to increased metastasis, high recurrence rate, and significant resistance to chemotherapy (e.g., Doxorubicin, DOX). Napabucasin (NAPA, a small organic molecule) is recognized to kill cancer stem cells by targeting the transcription factor STAT3 pathway and is currently in clinical trials... Overall, the hypoxia-responsive targeted polymersomes showed potent antitumor activity in the novel TNBC PDX animal model. With further developments, the targeted polymersomes might have translational potential as drug carriers for treating TNBC."

Clinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • NRP1

Synergistic suppression of gemcitabine resistance in PDAC by targeting STAT3 and ABCB11 (AACR 2025) - "Cytotoxicity assays evaluated the sensitivity of resistant and non-resistant PDAC cells to gemcitabine, napabucasin, and an EGFR inhibitor (gefitinib). The combination of gemcitabine, napabucasin, and glibenclamide synergistically suppresses tumor growth in resistant models, highlighting a potential therapeutic strategy to overcome gemcitabine resistance. Further studies are warranted to optimize combination therapies for clinical application."

Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • ABCB1 • STAT3

Napabucasin analogues with increased bioavailability and efficacy in fibrolamellar hepatocellular carcinoma (AACR 2025) - "Napabucasin is known to work in multiple signaling pathways and have been shown cytotoxic against both PDX and direct-from-patient FLC tumor cells. We anticipate that the organic synthesis and development of optimized Napabucasin analogues, along with the evaluation of their cytotoxicity and proliferation effectiveness compared to the parent compound, Napabucasin, will result in compounds with improved bioavailability and efficacy, particularly in FLC model cell lines (FLX1 and Huh7-Chimera)."

Clinical • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • DNAJB1 • PRKACA

NCX 4040 and napabucasin synergistically inhibits stemness in human prostate cancer (PCa) cellular models and potently targets transgenic murine PCa cells via inducing oxidative stress (AACR 2024) - "By investigating the ROS production, cell death and cell cycle mechanism using flow cytometric analysis, it was observed that the combination therapy synergistically induces cellular oxidative stress which causes cancer cells to undergo late apoptosis and halts the growth of Myc-Cap cells in G2M phase of cell cycle. In conclusion, our data suggests that combination therapy of NCX 4040 and napabucasin can be potential treatment strategy for PCa warranting further evaluation in in vivo models."

Oxidative stress • Preclinical • Genito-urinary Cancer • Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • ALDH1A1 • CD133 • CD44 • NANOG • POU5F1 • SOX2

Crosstalk between histone and DNA methylation in the development and progression of ALK+ ALCL (AACR 2024) - "Therefore, we look at the different gene expression changes after the inhibition of either meDNA, using a DNMT1 inhibitor (GSK3685032), or histone methylation, by EZH2 inhibitor (EPZ6438)...STAT3 inhibition, through napabucasin or by STAT3 silencing using Crispr-cas9 technology, resulted, likewise, in the downregulation of EZH2...Altogether, those data showed that NPM-ALK regulates EZH2 expression through STAT3. In conclusion, we provide, not only novel information on the mechanism in the downregulation of genes in ALK+ ALCL, but also new insight on the understanding of the epigenetics machinery and the crosstalk between histone and DNA methylation, for long time considered two mutually exclusive mechanisms, or even antagonist."

Epigenetic controller • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • ALK • EZH2 • NPM1

Targeting NAD(P)H: Quinone oxidoreductase 1 (NQO1) for colorectal cancer diagnosis and therapy (AACR 2025) - "Based on meta-analysis and a computational approach, NQO1 is a viable biomarker and a possible molecular target in CRC. In vitro, results showed that inhibiting NQO1 by BBI 608 decreased cell proliferation in both CRC cell lines. Knockout, overexpression, or site-directed mutagenesis is essential for a better understanding of BBI 608-targeted NQO1 and its amino acids."

Colorectal Cancer • Oncology • Solid Tumor • NQO1

Discovery of novel napabucasins bearing sulfonylpiperazine scaffolds as potent STAT3 inhibitors for the treatment of prostate cancer. (PubMed, Eur J Med Chem) - "In vivo studies revealed that YN11 significantly inhibited tumor growth without inducing considerable weight loss or apparent histopathological alterations in major organs. Our findings indicate that YN11 is a potent STAT3 inhibitor for treating PCa."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Recent progress of napabucasin as privileged scaffold in the discovery of anticancer agents. (PubMed, Eur J Med Chem) - "In this review, we systematically evaluated recent progress in the use of napabucasin as a privileged scaffold for the discovery of antitumor drugs, focusing on structure-activity relationships (SARs), structural modification strategies, and the illustration of tumor inhibitory pathways from a mechanistic perspective. By conducting multidimensional assessments, we propose feasible directions for developing napabucasins with improved pharmacological properties for cancer treatment."

Journal • Review • Oncology

BBI608 induces apoptosis in mucoepidermoid carcinoma cells by targeting a post-transcriptional regulatory mechanisms of myeloid cell leukemia-1. (PubMed, Arch Oral Biol) - "These findings demonstrate that BBI608 effectively inhibits MEC cell proliferation in vitro by inducing Mcl-1-dependent apoptosis. This suggests BBI608 warrants further investigation as a potential therapeutic agent for MEC."

Journal • Hematological Malignancies • Leukemia • Oncology • Salivary Gland Cancer • Squamous Cell Carcinoma • Targeted Protein Degradation • ANXA5 • CASP3 • MCL1

Discovery of a novel napabucasin derivative B16 as a potent STAT3 inhibitor for the treatment of triple-negative breast cancer. (PubMed, Eur J Med Chem) - "In vivo, B16 (10 mg/kg) reduced tumor volume by 82 % in a MDA-MB-231 xenograft model, outperforming napabucasin (50 % reduction in tumor volume), with no significant toxicity observed. These findings established B16 as a highly potent STAT3 inhibitor, offering a promising therapeutic strategy for TNBC."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Comparative Efficacy and Safety of Chemotherapeutic, Targeted, and Immunotherapy Drugs for Pancreatic Ductal Adenocarcinoma Treatment: A Network Meta-Analysis of RCTs (ACG 2025) - "Our analysis included 33 RCTs with a total sample size of 9,239 participants, comprising 5,636 in the treatment group and 3,603 in the control group. The included studies evaluated therapies such as Atezolizumab (79), Cabozantinib (76), Combined Chemotherapy (58), Demivistat + FOLFIRINOX (266), Durvalumab (3), EGPH20 + GEM-NABP (327), Erlotinib (518), FOLFIRINOX (433), Gemcitabine (2,090), Irinotecan (1,216), Mitazalimab (70), Nab-Paclitaxel (71), Nadunolimab (76), Napabucasin + GEM-NABP (565), Olaparib (124), Narilifox (766), Placebo (322), and Zenocutumab (454). The most significant survival benefit was observed with Irinotecan (OR = 4.96, 95% CI [1.45; 16.91],), while the least survival benefit was seen with Zenocutumab (OR = 0.38, 95% CI [0.03; 4.41],) compared to placebo."

Retrospective data • Novel Coronavirus Disease • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Synergistic MDM2-STAT3 Inhibition Demonstrates Strong Anti-Leukemic Efficacy in Acute Lymphoblastic Leukemia. (PubMed, Int J Mol Sci) - "In this study, human ALL cell lines-characterized by either wild-type or mutant tumor protein p53 (TP53) status-were treated with RG7388 (an MDM2 (mouse double minute 2 homolog) inhibitor) and BBI608 (a STAT3 (signal transducer and activator of transcription 3) inhibitor), both as single agents and in combination. This combinatorial approach augments apoptosis and tumor growth suppression, offering a promising avenue for expanding treatment options for a broader patient population. Further investigation is warranted to validate these preclinical findings and to explore translational implications in genetically diverse ALL subsets."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology